The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Martin Friedrichsen, Astrid Breitschaft, Sayeh Tadayon, Alicja Wizert, Dorthe Skovgaard, Martin Friedrichsen, Astrid Breitschaft, Sayeh Tadayon, Alicja Wizert, Dorthe Skovgaard
Abstract
Aim: To investigate the effects of once-weekly subcutaneous (s.c.) semaglutide 2.4 mg on gastric emptying, appetite, and energy intake in adults with obesity.
Materials and methods: A double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks. Gastric emptying was assessed using paracetamol absorption following a standardized breakfast. Participant-reported appetite ratings and Control of Eating Questionnaire (CoEQ) responses were assessed, and energy intake was measured during ad libitum lunch.
Results: The area under the concentration-time curve (AUC) for paracetamol 0 to 5 hours after a standardized meal (AUC0-5h,para ; primary endpoint) was increased by 8% (P = 0.005) with semaglutide 2.4 mg versus placebo at week 20 (non-significant when corrected for week 20 body weight; P = 0.12). No effect was seen on AUC0-1h,para , maximum observed paracetamol concentration, or time to maximum observed paracetamol concentration. Ad libitum energy intake was 35% lower with semaglutide versus placebo (1736 versus 2676 kJ; estimated treatment difference -940 kJ; P <0.0001). Semaglutide reduced hunger and prospective food consumption, and increased fullness and satiety when compared with placebo (all P <0.02). The CoEQ indicated better control of eating and fewer/weaker food cravings with semaglutide versus placebo (P <0.05). Body weight was reduced by 9.9% with semaglutide and 0.4% with placebo. Safety was consistent with the known profile of semaglutide.
Conclusions: In adults with obesity, once-weekly s.c. semaglutide 2.4 mg suppressed appetite, improved control of eating, and reduced food cravings, ad libitum energy intake and body weight versus placebo. There was no evidence of delayed gastric emptying at week 20, assessed indirectly via paracetamol absorption.
Keywords: GLP-1 analogue; appetite; control of eating; energy intake; food craving; gastric emptying; glucagon-like peptide-1; obesity; randomized trial; semaglutide.
Conflict of interest statement
M.F., S.T. and D.S. are employees and shareholders of Novo Nordisk, the sponsor of this trial; A.W. is an employee of Novo Nordisk. A.B. is an employee of Parexel International GmbH; Parexel International GmbH was paid by Novo Nordisk for assistance in conducting the study.
© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Figures
References
- Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1‐203.
- Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402‐424.
- American Diabetes Association . 8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes‐2020. Diabetes Care. 2020;43(Suppl 1):S89‐S97. [Addendum: Diabetes Care. 2020;43(8):1980‐1980].
- Nauck MA, Meier JJ. Are all GLP‐1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181(6):R211‐R234.
- O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double‐blind, placebo and active controlled, dose‐ranging, phase 2 trial. Lancet. 2018;392(10148):637‐649.
- Pi‐Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11‐22.
- Saxenda® Prescribing Information. Revised March 2020. . Accessed May 1, 2020.
- Saxenda® Summary of Product Characteristics. Revised January 2020. . Accessed May 1, 2020.
- Bessesen DH, Van Gaal LF. Progress and challenges in anti‐obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018;6(3):237‐248.
- Ozempic® Prescribing Information. Revised January 2020. . Accessed May 2, 2020.
- Ozempic® Summary of Product Characteristics; Revised February 2019. . Accessed March 20, 2020.
- Rybelsus® Prescribing Information. Revised January 2020. . Accessed July 27, 2020.
- Rybelsus® Summary of Product Characteristics. Revised June 2020. . Accessed June 5, 2020.
- Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once‐weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1‐7 trials. Diabetes Metab. 2019;45(5):409‐418.
- Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once‐weekly semaglutide versus daily canagliflozin as add‐on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double‐blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834‐844.
- Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once‐weekly semaglutide 1.0mg vs once‐daily liraglutide 1.2mg as add‐on to 1‐3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100‐109.
- Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once‐weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double‐blind, randomised, placebo‐controlled, parallel‐group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251‐260.
- Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as an add‐on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56‐week, double‐blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341‐354.
- Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once‐weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56‐week, open‐label, randomized clinical trial. Diabetes Care. 2018;41(2):258‐266.
- Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once‐weekly semaglutide versus once‐daily insulin glargine as add‐on to metformin (with or without sulfonylureas) in insulin‐naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open‐label, parallel‐group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355‐366.
- Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291‐2301.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834‐1844.
- Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open‐label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275‐286.
- Blundell J, Finlayson G, Axelsen M, et al. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242‐1251.
- Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429.
- Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050‐1061.
- Meier JJ, Rosenstock J, Hincelin‐Méry A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open‐label trial. Diabetes Care. 2015;38(7):1263‐1273.
- Maselli DB, Camilleri M. Effects of GLP‐1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol. 2021;1307:171‐192.
- Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610‐619.
- Willems M, Quartero AO, Numans ME. How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig Dis Sci. 2001;46(10):2256‐2262.
- Dalton M, Finlayson G, Hill A, Blundell J. Preliminary validation and principal components analysis of the control of eating questionnaire (CoEQ) for the experience of food craving. Eur J Clin Nutr. 2015;69(12):1313‐1317.
- Lee WH, Kramer WG, Granville GE. The effect of obesity on acetaminophen pharmacokinetics in man. J Clin Pharmacol. 1981;21(7):284‐287.
- Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. Obesity, sex, and acetaminophen disposition. Clin Pharmacol Ther. 1982;31(6):783‐790.
- Dahl K, Blundell J, Gibbons C, et al. Oral semaglutide improves postprandial glucose and lipid metabolism and delays first‐hour gastric emptying in subjects with type 2 diabetes. Abstract 50. Presented at the 55th Annual Meeting of the European Association for the Study of Diabetes, September 16–20, 2019, Barcelona, Spain. . Accessed May 13, 2020.
- Tong J, D'Alessio D. Give the receptor a brake: slowing gastric emptying by GLP‐1. Diabetes. 2014;63(2):407‐409.
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon‐like peptide‐1. Cell Metab. 2018;27(4):740‐756.
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155.
Source: PubMed